WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The trial is a pharmacodynamic study to determine the effect of a novel regimen of aspirin 20
mg BD plus rivaroxaban 2.5 mg BD on haemostasis, fibrin clot dynamics, inflammatory markers,
platelet function and arachidonic acid metabolites when compared to standard regimens of
aspirin 75 mg OD and aspirin 75 mg OD plus rivaroxaban 2.5 mg BD.
In a randomised open-label three-period crossover design, patient participants receiving
aspirin 75 mg OD for secondary prevention of IHD will be randomised 1:1 to receive one of two
sequences of aspirin: aspirin 75 mg OD, then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD,
then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD; or aspirin 75 mg OD, then aspirin 75 mg OD
plus rivaroxaban 2.5 mg BD, then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD.
At the end of each 14(-2) day medication period, they will attend a study visit at which
blood and urine samples will be obtained, and bleeding time measured, before and 2 hours
after the last dose of IMP of the treatment period. The samples will be tested for fibrin
clot dynamics; inflammatory markers and cytokines; prostanoids; and platelet function.
Participants will be transitioned back to standard-of-care aspirin 75 mg OD at the end of the
third treatment period and followed up by telephone call 14(-2) days later.